Last reviewed · How we verify
NCT05091866
Natural Progesterone for the Treatment of Recurrent Glioblastoma
EARLY_PHASE1 trial testing Quality-of-Life Assessment in Gliosarcoma in 4 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2026
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 4 |
| Start date | 11 April 2022 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Quality-of-Life Assessment
- Questionnaire Administration
- Therapeutic Progesterone — full drug profile →
Conditions studied
- Gliosarcoma — all drugs for Gliosarcoma →
- Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
Sponsor
Emory University
Who can join
18 and older, any sex, with Gliosarcoma or Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05091866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Quality-of-Life Assessment
Trials testing the same drug.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT06710418 — Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi · NA · recruiting
- NCT06500481 — Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- · Phase 3 · recruiting
- NCT05539365 — Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast · Phase 2 · withdrawn
- NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
Other recruiting trials for Gliosarcoma
Currently open trials in the same condition.
- NCT05095376 — Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation T · Phase 3 · active not recruiting
- NCT05084430 — Study of Pembrolizumab and M032 (NSC 733972) · Phase 1, PHASE2 · recruiting
- NCT04528680 — Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma · Phase 1, PHASE2 · active not recruiting
- NCT04555577 — Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmet · Phase 1 · recruiting
- NCT04216329 — Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma · Phase 1 · active not recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05091866 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05091866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing